(XRAY) Dentsply Sirona - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 2.045m USD | Total Return: -36.5% in 12m
Avg Turnover: 59.5M
EPS Trend: -84.6%
Qual. Beats: 0
Rev. Trend: -92.3%
Qual. Beats: 2
Warnings
Interest Coverage Ratio -5.3 is critical
Altman Z'' -1.35 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Dentsply Sirona Inc. (XRAY) is a global manufacturer of dental equipment, consumables, and specialized healthcare products. The company operates through four primary segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. Its portfolio ranges from CAD/CAM restoration systems (CEREC) and imaging equipment to endodontic tools, clear aligners, and urological medical devices.
The company utilizes a diversified business model that combines high-margin capital equipment sales with recurring revenue from dental consumables. As a major player in the Health Care Supplies sub-industry, Dentsply Sirona benefits from the increasing integration of digital workflows and 3D visualization tools in modern clinical dentistry. This digital shift allows practitioners to consolidate diagnostic and treatment planning within a single ecosystem.
For more detailed insights into the companys valuation and market positioning, consider reviewing the data available on ValueRay. Headquartered in Charlotte, North Carolina, Dentsply Sirona maintains a global footprint, serving both the professional dental market and specific chronic care medical sectors.
- Macroeconomic pressure on elective dental procedures impacts high-margin equipment sales
- Expansion of DS Core cloud platform drives recurring software revenue growth
- Competitive clear aligner pricing affects Orthodontic and Implant Solutions segment margins
- Supply chain stabilization and manufacturing efficiencies reduce operational expenditure volatility
- Regulatory compliance and internal accounting investigations influence investor confidence and valuation
| Net Income: -628.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -2.61 > 1.0 |
| NWC/Revenue: 17.33% < 20% (prev 4.97%; Δ 12.36% < -1%) |
| CFO/TA 0.05 > 3% & CFO 268.0m > Net Income -628.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (199.9m) vs 12m ago 0.05% < -2% |
| Gross Margin: 48.93% > 18% (prev 0.52%; Δ 4.84k% > 0.5%) |
| Asset Turnover: 65.27% > 50% (prev 61.47%; Δ 3.80% > 0%) |
| Interest Coverage Ratio: -5.32 > 6 (EBITDA TTM -127.0m / Interest Expense TTM 90.0m) |
| A: 0.12 (Total Current Assets 1.84b - Total Current Liabilities 1.21b) / Total Assets 5.23b |
| B: -0.30 (Retained Earnings -1.57b / Total Assets 5.23b) |
| C: -0.08 (EBIT TTM -479.0m / Avg Total Assets 5.64b) |
| D: -0.57 (Book Value of Equity -2.23b / Total Liabilities 3.91b) |
| Altman-Z'' = -1.35 = CCC |
| DSRI: 1.04 (Receivables 622.0m/604.0m, Revenue 3.68b/3.72b) |
| GMI: 1.05 (GM 48.93% / 51.57%) |
| AQI: 0.88 (AQ_t 0.46 / AQ_t-1 0.52) |
| SGI: 0.99 (Revenue 3.68b / 3.72b) |
| TATA: -0.17 (NI -628.0m - CFO 268.0m) / TA 5.23b) |
| Beneish M = -3.20 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 9.99 with a total of 5,602,876 shares traded.
Over the past week, the price has changed by +1.73%,
over one month by -16.47%,
over three months by -21.40% and
over the past year by -36.53%.
Dentsply Sirona has received a consensus analysts rating of 3.35. Therefore, it is recommended to hold XRAY.
- StrongBuy: 2
- Buy: 2
- Hold: 13
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 13.6 | 36.1% |
P/E Forward = 7.2359
P/S = 0.5556
P/B = 1.5511
P/EG = 0.7238
Revenue TTM = 3.68b USD
EBIT TTM = -479.0m USD
EBITDA TTM = -127.0m USD
Long Term Debt = 2.01b USD (from longTermDebt, last quarter)
Short Term Debt = 230.0m USD (from shortTermDebt, last quarter)
Debt = 2.43b USD (from shortLongTermDebtTotal, last quarter) + Leases 95.0m
Net Debt = 2.24b USD (calculated: Debt 2.43b - CCE 190.0m)
Enterprise Value = 4.28b USD (2.05b + Debt 2.43b - CCE 190.0m)
Interest Coverage Ratio = -5.32 (Ebit TTM -479.0m / Interest Expense TTM 90.0m)
EV/FCF = 41.17x (Enterprise Value 4.28b / FCF TTM 104.0m)
FCF Yield = 2.43% (FCF TTM 104.0m / Enterprise Value 4.28b)
FCF Margin = 2.83% (FCF TTM 104.0m / Revenue TTM 3.68b)
Net Margin = -17.06% (Net Income TTM -628.0m / Revenue TTM 3.68b)
Gross Margin = 48.93% ((Revenue TTM 3.68b - Cost of Revenue TTM 1.88b) / Revenue TTM)
Gross Margin QoQ = 48.52% (prev 46.10%)
Tobins Q-Ratio = 0.82 (Enterprise Value 4.28b / Total Assets 5.23b)
Interest Expense / Debt = 3.71% (Interest Expense 90.0m / Debt 2.43b)
Taxrate = 21.0% (US default 21%)
NOPAT = -378.4m (EBIT -479.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.53 (Total Current Assets 1.84b / Total Current Liabilities 1.21b)
Debt / Equity = 1.84 (Debt 2.43b / totalStockholderEquity, last quarter 1.32b)
Debt / EBITDA = -17.61 (negative EBITDA) (Net Debt 2.24b / EBITDA -127.0m)
Debt / FCF = 21.50 (Net Debt 2.24b / FCF TTM 104.0m)
Total Stockholder Equity = 1.52b (last 4 quarters mean from totalStockholderEquity)
RoA = -11.14% (Net Income -628.0m / Total Assets 5.23b)
RoE = -20.27% (Net Income TTM -628.0m / Total Stockholder Equity 3.10b)
RoCE = -9.38% (EBIT -479.0m / Capital Employed (Equity 3.10b + L.T.Debt 2.01b))
RoIC = -8.90% (negative operating profit) (NOPAT -378.4m / Invested Capital 4.25b)
WACC = 6.42% (E(2.05b)/V(4.47b) * Re(10.55%) + D(2.43b)/V(4.47b) * Rd(3.71%) * (1-Tc(0.21)))
Discount Rate = 10.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -64.44 | Cagr: -2.35%
[DCF] Terminal Value 73.10% ; FCFF base≈173.6m ; Y1≈152.2m ; Y5≈123.0m
[DCF] Fair Price = N/A (negative equity: EV 1.97b - Net Debt 2.24b = -261.7m; debt exceeds intrinsic value)
EPS Correlation: -84.57 | EPS CAGR: -7.45% | SUE: 0.0 | # QB: 0
Revenue Correlation: -92.26 | Revenue CAGR: -3.43% | SUE: 2.07 | # QB: 2
EPS current Quarter (2026-06-30): EPS=0.35 | Chg30d=-6.92% | Revisions=-50% | Analysts=16
EPS next Quarter (2026-09-30): EPS=0.37 | Chg30d=+0.76% | Revisions=+0% | Analysts=16
EPS current Year (2026-12-31): EPS=1.42 | Chg30d=-0.85% | Revisions=-38% | GrowthEPS=-11.2% | GrowthRev=-2.6%
EPS next Year (2027-12-31): EPS=1.54 | Chg30d=-1.16% | Revisions=-20% | GrowthEPS=+8.2% | GrowthRev=+2.1%
[Analyst] Revisions Ratio: -50%